Welcome to our dedicated page for EXELIXIS SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
Exelixis, Inc. reported strong first‑quarter 2026 growth, driven mainly by its cabozantinib franchise. Total revenues rose to $610.8 million from $555.4 million a year earlier, with net product revenues increasing to $555.0 million. Net income climbed to $210.5 million, up from $159.6 million, and diluted EPS improved to $0.79 from $0.55, reflecting operating leverage as total operating expenses stayed roughly flat.
The company ended the quarter with $1.43 billion in cash, cash equivalents and marketable securities and continued returning capital to shareholders, repurchasing common stock for $430.4 million of cash in the quarter as part of a broader buyback program. Exelixis also highlighted progress in its oncology pipeline, including zanzalintinib, which has an FDA‑accepted New Drug Application in metastatic colorectal cancer and multiple ongoing pivotal and phase 2 studies across several tumor types.
Exelixis reported strong first quarter 2026 results and expanded its stock repurchase plans. Total revenues were $610.8 million, up from $555.4 million a year earlier, driven by net product revenues of $555.0 million, largely from the U.S. cabozantinib franchise. GAAP net income was $210.5 million, or $0.79 per diluted share, while non-GAAP diluted EPS was $0.87.
The company reaffirmed 2026 guidance, including total revenues of $2.525–$2.625 billion and net product revenues of $2.325–$2.425 billion, with an effective tax rate of 21–23%. Exelixis’ board authorized a new $750 million stock repurchase program through December 31, 2027, after repurchasing $590.6 million under its October 2025 program and $2.59 billion cumulatively since March 2023, retiring 86.8 million shares.
Pipeline momentum continued as the FDA accepted the NDA for zanzalintinib in previously treated metastatic colorectal cancer, with a PDUFA target action date of December 3, 2026. Multiple pivotal trials, including STELLAR-303, STELLAR-304, STELLAR-311, STELLAR-316 and Merck’s LITESPARK-033 and -034, are underway or planned across colorectal, renal cell, neuroendocrine and other tumors.
Exelixis Inc Schedule 13G shows Vanguard Capital Management reported beneficial ownership of 13,233,247 shares of common stock, representing 5.09% of the class. The filing states Vanguard has sole dispositive power over 13,233,247 shares and sole voting power over 1,974,263 shares.
The filing lists Vanguard affiliates and clarifies holdings include shares held for funds and managed accounts. The form is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.
Exelixis, Inc. calls a virtual 2026 Annual Meeting on May 26, 2026, asking stockholders to elect eleven directors, ratify Ernst & Young LLP as auditor, approve a 2,000,000‑share increase to the 2017 Equity Incentive Plan, and give an advisory Say‑on‑Pay vote.
The company highlights 2025 as its ninth consecutive year of operating profitability, with total revenue of $2.32 billion, up 7% year over year, driven by the cabozantinib franchise. Exelixis filed its first New Drug Application for zanzalintinib, accepted for FDA review in early 2026, and continued pivotal trials.
Management emphasizes disciplined capital allocation, including share repurchases, and a one‑time broad‑based equity grant to reinforce ownership culture and retention. The proxy details board composition, committee structure, director independence, and extensive governance, risk oversight and compensation frameworks aligned to long‑term oncology growth.
Exelixis Inc ownership disclosure: The Vanguard Group filed an amendment stating it beneficially owns 0 shares of Exelixis common stock, representing 0% of the class. The filing notes an internal realignment on January 12, 2026 and cites "in accordance with SEC Release No. 34-39538 (January 12, 1998)."
The filing is signed by Ashley Grim, Head of Global Fund Administration, and lists The Vanguard Group's address in Malvern, Pennsylvania.
Aftab Dana reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. executive vice president of research and development Dana Aftab reported an equity compensation grant in the form of restricted stock units (RSUs). The award covers 52,018 shares of common stock, granted under the company’s 2017 Equity Incentive Plan at no cash cost.
These RSUs will vest as to one quarter of the original grant on May 15, 2027, and one quarter on each following May 15 until fully vested. Following this grant, Aftab’s directly held common stock position, including previously granted RSUs and performance-based RSUs, totals 668,124 shares, of which 466,061 shares relate to unvested RSUs and a prior performance-based award. In addition, 5,835 shares are held indirectly through the Exelixis 401(k) Plan as of a statement dated February 26, 2026.
EXELIXIS, INC. Executive Vice President and CFO Christopher J. Senner reported an equity compensation award in the form of restricted stock units tied to the company’s common stock. The filing shows an acquisition of 52,018 shares of common stock at a price of $0.00 per share, representing RSUs granted under the Exelixis, Inc. 2017 Equity Incentive Plan that will be issued upon vesting. These RSUs vest in four equal annual installments, beginning May 15, 2027 and then each May 15 thereafter until fully vested. After this grant, Senner directly owns or has rights to 1,028,110 shares of common stock, including 479,708 shares that will be issued upon vesting of previously granted RSUs and performance-based restricted stock units. He also indirectly holds 2,723 shares through the Exelixis, Inc. 401(k) Plan as of February 26, 2026.
Hefti Brenda reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. senior vice president and general counsel Brenda Hefti received an equity award in the form of restricted stock units (RSUs) tied to the company’s common stock. The grant covers 23,119 shares that will be issued as the RSUs vest over time.
According to the grant terms, one-quarter of the original RSU amount will vest on May 15, 2027, with additional one-quarter installments vesting on each May 15 thereafter until fully vested. Following this award, Hefti has 119,631 shares of common stock reported as directly owned, including shares underlying previously granted RSUs and performance-based restricted stock units, and 5,527 shares held indirectly through the company’s 401(k) plan.
Haley Patrick J. reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. executive Patrick J. Haley, EVP, Commercial, received an equity grant of 40,459 restricted stock units (RSUs) of common stock. The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan and carry no purchase price.
The award will vest as to one-quarter of the original RSU share amount on May 15, 2027, and one-quarter on each May 15 thereafter until fully vested. Following this grant, a total of 422,367 shares of common stock are scheduled to be issued to Haley upon vesting of RSUs and a performance-based restricted stock unit award granted on March 31, 2025.
EXELIXIS, INC. President and CEO Michael Morrissey reported both an equity award and a charitable gift of company stock. On February 26, 2026, he was granted 160,437 restricted stock units (RSUs) under the Exelixis, Inc. 2017 Equity Incentive Plan at no cash cost.
The RSUs will vest as to one-quarter of the original shares on May 15, 2027 and then one-quarter on each May 15 thereafter until fully vested. Following this grant, 1,614,552 shares of common stock are scheduled to be issued to him upon vesting of RSUs and a performance-based restricted stock unit award granted on March 31, 2025.
Separately, on February 24, 2026, shares held by the Morrissey Family Living Trust were used to make a bona fide gift of 100,278 shares of Exelixis common stock to the Bombora Rise Foundation. In addition, 17,728 shares are held for his benefit under the Exelixis, Inc. 401(k) Plan as of February 26, 2026.